April Client Spotlight
National Cardiac Inc. (NCI)
At TGG, we develop close relationships with our clients.
Through our weekly check-ins and intense scrutiny of a company’s accounts, we get pretty attached to our clients’ success! So, without further ado, we are delighted to shine our April client spotlight on National Cardiac Inc. (NCI).
The team at TGG has been working with National Cardiac for over 2.5 years and in that time, they have had some exciting breakthroughs that will change the way cardiac health is administered across the country. We recently interviewed the CEO of the company, Steve Kenney, about their current innovations and plans for the future. Here are some excerpts from that interview:
Q: We hear there are some exciting new releases on the horizon for NCI, can you share a little about what is in the works?
A: NCI has received FDA clearance for the novel cardiac monitoring wearable patch named Liba 3. This new approach to remote cardiac monitoring will replace 30-year-old technology widely used today.
- Remote cardiac monitoring wearables traditionally send short bursts of information to a physician monitoring a patient’s cardiac health through wireless patches the patient wears on their chest. There have been issues with data loss and missed arrhythmias in the past.
- The Liba 3 patch has been designed to make cardiac monitoring much more easily wearable. The integrated technology accesses the Cloud to bring immediate, secure monitoring information to a physician.
Q: When will this exciting new technology be rolled out?
A: NCI is very excited to partner with one or more industry leaders in technology and distribution to launch the Liba 3 in the last quarter of 2020.
Q: Where do you see NCI in the coming 1 – 5 years?
A: We would like to build NCI into a very attractive acquisition candidate for one of the large companies who are currently trying to compete in this space, which has not seen marked innovation in the last 30+ years. An acquisition is certainly our overall goal.
